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Abstract
Background: Younger age at onset of breast development, which has been declining in recent decades, is
associated with increased breast cancer risk independent of age at menarche. Given the need to study the drivers
of these trends, it is essential to validate methods to assess breast onset that can be used in large-scale studies
when direct clinical assessment of breast onset is not feasible.
Methods: Breast development is usually measured by Tanner stages (TSs), assessed either by physical examination
or by mother’s report using a picture-based Sexual Maturation Scale (SMS). As an alternative, a mother-reported
Pubertal Development Scale (PDS) without pictures has been used in some studies. We compared agreement of
SMS and PDS with each other (n = 1022) and the accuracy of PDS with clinical TS as a gold standard for the subset
of girls with this measure (n = 282) using the LEGACY cohort. We further compared prediction of breast onset
using ROC curves and tested whether adding urinary estrone 1-glucuronide (E1G) improved the AUC.
Results: The agreement of PDS with SMS was high (kappa = 0.80). The sensitivity of PDS vs clinical TS was 86.6%.
The AUCs for PDS alone and SMS alone were 0.88 and 0.79, respectively. Including E1G concentrations improved
the AUC for both methods (0.91 and 0.86 for PDS and SMS, respectively).
Conclusions: The PDS without pictures is a highly accurate, sensitive, and specific method for assessing breast
onset, especially in settings where clinical TS is not feasible. In addition, it is comparable to SMS methods with
pictures and thus easier to implement in large-scale studies, particularly phone-based interviews where pictures
may not be available. Urinary E1G can improve accuracy over than PDS or SMS alone.
Keywords: Breast development, Breast cancer, Measurement, Puberty
Background
Puberty is an important stage of development that im-
pacts future breast cancer risk [1]. Recent increases in
the incidence of early-onset invasive breast cancer [2]
may be related to recent declines in the age at initiation
of breast development [3]. Earlier age at breast onset, in-
dependent of age at menarche, which unlike age at
breast development has been more stable in recent de-
cades, has been found to be associated with an increased
risk for breast cancer [4]. Large-scale epidemiologic
studies investigating factors that may explain risk of
early breast onset are needed across diverse populations.
Therefore, it is important to use methods that can assess
the timing of breast onset that are both sensitive and
specific as well as feasible in large-population studies.
Because timing of breast onset has been shown to vary
by ethnicity and obesity [5–7], it is also important to
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evaluate whether different methods to assess the onset
of breast development vary by these factors.
Breast development can be measured by physical
examination by clinicians or through guardian report or
self-report based on questionnaires, either with or with-
out picture prompts. Clinicians perform a visual and
physical assessment, sometimes with palpation, of breast
development according to Tanner stages (TSs) established
in 1969 [8]. Although clinician assessment via physical
examination is considered the gold standard [9, 10], self-
reports and guardian reports are often used in lieu of the
physical examination, especially in large-scale epidemio-
logical studies in which conducting physical examinations
is often not feasible. One such method is the Sexual Mat-
uration Scale (SMS), a questionnaire-based tool that asks
respondents to rate breast development based on pictures
that correspond with the five TSs [11]. Another commonly
used questionnaire-based instrument is the Pubertal De-
velopment Scale (PDS) [12]. A key advantage of the PDS
is that it is question-based and does not involve pictures
and can therefore be queried over the phone and/or more
easily included in questionnaires.
Given the need to have scalable methods that accur-
ately reflect pubertal development stage, the purpose of
the present study was to compare the SMS and PDS
with clinical TS to assess the specificity and sensitivity of
reported measures of breast onset. Given that estrogens
lead to increased epithelial proliferation in terminal end
buds of the mammary gland, resulting in the onset of
breast development [13], a secondary aim of this study
was to evaluate whether the assessment of hormonal
measures in premenarcheal girls increases the validity of
guardian-reported methods of breast onset. Estrone 1-
glucuronide (E1G), an estrogen metabolite in urine, is an
indicator of total circulating estrogens, which rise before
puberty [14]. Previous studies have found both the PDS
and SMS to be accurate measures of breast development
[15–18], but none have simultaneously compared SMS,
PDS, and hormonal biomarkers with clinical TS.
Methods
Study population
The LEGACY Girls Study is a five-site study of pubertal
development in 1040 girls ages 6–13 years at recruit-
ment, half of whom have a family history of breast can-
cer (for details, see [19, 20]). Prior validation studies
have not been conducted in cohorts enriched with indi-
viduals who have a family history of breast cancer. Be-
cause pubertal development measures are important to
breast cancer risk, it is essential to evaluate whether dif-
ferential measurement error exists based on breast can-
cer family history. Across all five study sites,
classification of pubertal timing was based on the
Growth and Development Questionnaire, which includes
both the PDS [12] and SMS [11]. Mothers/guardians for
girls of all ages and girls aged 10 years or older com-
pleted the questionnaire every 6 months. Because 97% of
girls participated with their biological mother [19], we
refer to them as the mother for the remainder of the
paper. For the purpose of this study, we used the first
available mother reports of breast onset.
Tanner staging
TS assessment includes evaluation of the development
of both breasts and areolas, with TS1 representing pre-
pubertal development, TS2 representing the onset of
breast development, TS3 representing further enlarge-
ment of breast and areola without separation of their
contour, TS4 representing the areola and papilla forming
a secondary mound above the level of the breast, and
TS5 representing full breast maturity.
Pubertal Development Scale
Using the PDS, mothers assessed breast development by
responding to the question, “How far along is your
daughter in the development of her breasts?” with five
possible answer options: (1) has not yet started breast
development, (2) barely started breast development, (3)
breast development is definitely underway, (4) breast de-
velopment seems complete, or (5) no answer. Option 2,
“barely started,” corresponds with the onset of breast de-
velopment and TS2 [12].
Sexual Maturation Scale
The SMS instructions were as follows: “The drawings
below show five different stages of breast development.
A girl can go through each of the five stages, although
some girls skip some stages. Look at each drawing, and
read the description. Which of these drawings looks
most like your daughter’s stage of development?”
Mothers rated their daughter’s breast development by
selecting one of five line drawings showing TS1–TS5
[11]. We collapsed stages 4 and 5 to convert the SMS 5-
point scale into a 4-point scale to directly compare with
the PDS. TS2 marks the onset of breast development.
Clinical TS
At two study sites, trained research staff or a physician
performed standardized clinical breast Tanner staging on
282 girls [21]. Three clinical raters from New York and
one from Utah were trained concurrently on the deter-
mination of breast TS using visual inspection along with
palpation when necessary. If it was difficult to distin-
guish between breast bud development (TS2) and fat tis-
sue, then the breast was palpated with the girl’s
permission, and a second score based on both
visualization and palpation was recorded. As in the
SMS, breast onset is marked by TS2. Clinician interrater
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reliability for Tanner breast stage was high, with
weighted kappa scores ranging from 0.93 to 1.00 and
kappa scores for T2+ vs T1 of 0.94–1.00 [21].
Hormone measurement
Microtiter plate competitive enzyme immunoassays
(EIAs) were used to measure E1G, which was assessed
in a first-morning void provided by premenarcheal girls
at the same clinical visit as when maternal PDS and
SMS and clinical TS were reported. The E1G EIA uses a
polyclonal capture antibody R522-2 from Coralie Mun-
roe at the University of California (Davis, CA, USA).
The competitor for this assay is E1G conjugated to
horseradish peroxidase [22]. An endpoint substrate color
reaction is developed with azino-bis-ethylbenzthiazoline
sulfonic acid and peroxidase. E1G standards from
Sigma-Aldrich (St. Louis, MO, USA) were used for the
standard curves, and high and low internal controls were
in-house samples. The interassay coefficients of variation
for high and low internal controls for the E1G assay
were 14.7% and 13.1%, respectively. The sensitivity of
the E1G assay was 5.2 ng/ml. All urine samples were
corrected for specific gravity using a hand refractometer
(NSG Precision Cells, Inc., Farmingdale, NY, USA), and
the concentration determined from the assay was di-
vided by the specific gravity to correct for hydration sta-
tus [23–26].
Additional covariates
At each study visit, height and weight were measured
twice by trained research staff. Averaging the two mea-
sures, we calculated age-specific height, weight, and
body mass index (BMI) percentiles based on Centers for
Disease Control and Prevention (CDC) growth charts
[27]. Girls were classified as overweight if their BMI was
equal to or above the 85th percentile. Girls were classi-
fied as having a family history of breast cancer if the par-
ticipating mother reported a breast cancer family history
in the daughter’s first- or second-degree relatives.
Statistical models
We calculated percent agreement and kappa statistics
between the first available mother’s report of breast on-
set using the question-only PDS and the picture-based
SMS. We also assessed the sensitivity and specificity of
PDS using the clinical TS as the gold standard. To
examine whether mother’s reports for some subgroups
of girls were less accurate, we assessed whether age,
breast cancer family history, BMI, or race/ethnicity influ-
enced the accuracy of the mother’s classification. We
generated ROC curves to compare the PDS and SMS
with clinical TS. We compared assessment of breast on-
set in two ways: we compared T2 with T1 and T2–T5
(T2+) with T1. We tested if adding other covariates
improved the AUC of these models. Using Weibull
models, we compared the median age at breast onset de-
rived from the two mother’s report methods (PDS and
SMS) with the median age from the clinical TS in a sub-
set of girls who had all three measures at baseline (n =
200). We also compared the different pubertal staging
methods with first morning urinary E1G concentrations
that were collected at the same clinical visit as the PDS,
SMS, and clinical TS. We used linear regression to com-
pare E1G, after logarithmic transformation, at each stage
of breast development as reported by mothers using the




In the overall cohort (N = 1022 with complete informa-
tion; see Additional file 1: Table S1), PDS and SMS re-
ports of breast onset stage were in high agreement
(89.6%) (Table 1). The overall weighted kappa value was
0.80. The weighted kappa value was higher for reports
from mothers of girls younger than 10 years old than
from mothers of girls aged 10 years or older (Table 1).
PDS vs clinical TS
PDS was also highly accurate in relation to clinical TS
(87.9%) (Table 2). The overall weighted kappa value was
0.80, and sensitivity and specificity were 86.6% and
89.6%, respectively. Sensitivity was lower for reports
from mothers of younger daughters than older daughters
(62.5% vs 91.8%), but specificity was higher (95.8% vs
45%). Sensitivity was similar between mothers of girls
with positive and negative family histories. Mothers of
overweight girls (as defined on the CDC 85th percentile)
had higher sensitivity (96.9% vs 83.0%) but lower specifi-
city than mothers of nonoverweight girls (65.0% vs
93.1%).
Hormone concentration by pubertal staging
Mean concentrations of E1G increased incrementally
with each maturity stage as measured by PDS, SMS, or
clinical TS (Table 3). Hormones were statistically higher
in each subsequent stage for each assessment method.
E1G concentrations were 0.80–0.88 ng/ml higher in girls
rated at T2+ than girls in T1 across all measures. Girls
with breast onset (T2+) according to any of the three
different methods had E1G levels above 2 ng/ml, sug-
gesting a possible hormonal threshold for breast onset.
The distribution of E1G in the subset of girls (n = 153)
with all three (PDS, SMS, and clinical TS) measures of
breast development and a hormone measurement avail-
able is shown in Fig. 1. Mean E1G values were 1.2 ng/ml
in girls at stage 1 and 2.3 ng/ml in girls at T2+ when all
three methods of breast onset were concordant. Values
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ranged from 1.5 to 1.8 ng/ml for girls with at least one
discordant measure.
Using clinical TS as the gold standard, the AUC (TS1
vs TS2+) for PDS alone was higher (0.88) than for SMS
(0.78) alone (Table 4) or E1G alone (0.77). The AUCs for
both PDS and SMS improved with the inclusion of hor-
mone measurements (AUC = 0.91 and 0.86 for PDS and
SMS, respectively). Adding additional predictors such as
race/ethnicity, overweight status, and family history im-
proved the AUC by 1% or less.
Impact on predicted median age at breast onset
The median ages (IQR) at breast onset were 9.9 years
(9.1–10.5), 10.8 (9.7–11.8), and 10.1 (9.0–11.1) as assessed
by the PDS, SMS, and clinical TS, respectively (Fig. 2).
This translates to PDS underestimating age at breast onset
by 2.4 months and SMS overestimating it by 8.4 months.
Discussion
Our results demonstrate that breast onset determined by
mother’s report using the PDS corresponds well with
both clinical TS (the existing gold standard) and the
physiological changes in gonadal steroid hormone con-
centrations that drive pubertal maturation. Furthermore,
the discrimination from mother’s report of breast onset
using the PDS in predicting TS2+ was better than using
mother’s report of SMS. Our findings also suggest that
E1G in combination with mother’s report further im-
proves the discrimination of breast onset. Although the
majority of puberty studies use clinical TS to assess breast
onset [28–33], large-scale studies of pubertal development
using mother’s report without a clinical visit can produce
accurate and valid measures of breast onset, particularly
when additional hormone measures are added.
Mother’s report using PDS had higher discrimination,
agreement, and accuracy than mother’s report using
SMS. We previously published the kappa values and per-
cent agreement between mother’s report using SMS with
clinical TS in the same cohort and found agreement
with clinical TS to be 73% compared with the 88% re-
ported here with PDS [21]. Mothers were less accurate
at identifying TS2+ when using SMS, perhaps because
the pictures of TS2 capture size in addition to areolar
development, leading mothers to downgrade their
Table 1 Agreement between Pubertal Development Scale and Sexual Maturation Scale methods of assessing breast onset, by
sample characteristics in the LEGACY Girls Study
Description PDSa vs SMSb
2+ vs 1
No. of subjects Agreement Kappa value 95% CI
All ages combined 1022 89.6 0.8 0.7–0.9
Daughter aged < 10 years 500 92.4 0.7 0.6–0.8
Daughter aged ≥ 10 years 522 87 0.5 0.4–0.6
Family history
Positive 529 90.9 0.8 0.7–0.9
Negative 493 88.2 0.8 0.7–0.9
BMI percentilec
BMI ≥ 85th percentile 188 90.4 0.8 0.7–0.9
BMI < 85th percentile 815 89.6 0.8 0.7–0.9
Race/ethnicity
White non-Hispanic 636 89.8 0.8 0.7–0.9
Hispanic 189 89.9 0.8 0.7–0.9
Other (black, Asian, other) 197 88.8 0.7 0.7–0.9
Site
Philadelphia 152 92.3 0.7 0.6–0.8
New York 166 92.2 0.7 0.6–0.8
Utah 161 92.8 0.7 0.6–0.8
Ontario 191 93.3 0.8 0.7–0.9
California 352 91.2 0.7 0.6–0.8
Abbreviations: BMI Body mass index, PDS Pubertal Development Scale, SMS Sexual Maturation Scale
aPDS is a questionnaire-based assessment of breast development without pictures
bSMS is a questionnaire-based assessment of breast development that uses pictures to illustrate the five Tanner stages of breast development
cMissing BMI for 19 girls
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daughter’s breast development. However, the PDS ques-
tions preceded the SMS pictures, and this order of ad-
ministration may have affected the comparison as well.
The kappa value and percent accuracy of mother’s re-
ports of breast onset using either the PDS or SMS com-
pared with clinical TS were consistent and higher in our
study than those previously reported in other studies of
pubertal development [15–17]. Specifically, in a study
consisting of 78 girls (aged 9–14 years), the kappa value
between mother’s report using either PDS or SMS com-
pared with clinical TS was 0.36 with 47–49% agreement
[15]. The age range of girls in our study was wider (6–16
years) than in other studies, allowing us to assess differ-
ences in accuracy according to age. We observed that
mothers of young daughters (< 10 years old) were accur-
ate in reporting the absence of breast onset (specificity)
and mothers of older daughters (≥ 10 years old) were ac-
curate in reporting the presence of breast onset (sensi-
tivity); thus, the wider age range and more mothers of
young (6–9 years old) and older (14–16 years old)
daughters in our cohort may explain the higher overall
agreement in our study. Although we were unable to
compare PDS and SMS with clinical TS in our full co-
hort, the sample size of the subset with all available
Table 2 Accuracy of Pubertal Development Scale method of assessing breast onset compared with clinical Tanner scale, by sample
characteristics in the LEGACY Girls Study
Description PDSa vs clinical TSb
2+ vs 1
No. of subjects Accuracy (%) Kappa value 95% CI Sensitivity Specificity
All ages combined 282 87.9 0.8 0.7–0.9 86.6 89.6
Daughter aged < 10 years 165 91.9 0.6 0.4–0.8 62.5 95.8
Daughter aged ≥ 10 years 117 83.8 0.4 0.2–0.6 91.8 45
Family history
Positive 122 89.3 0.8 0.6–1.0 86.6 92.2
Negative 155 87.5 0.7 0.5–0.9 86.7 88
BMI percentilec
BMI ≥ 85th percentile 50 84.6 0.7 0.4–0.9 96.9 65
BMI < 85th percentile 223 89.1 0.8 0.7–0.9 83 93.1
Race/ethnicity
White non-Hispanic 189 87.9 0.7 0.6–0.8 100 100
Hispanic 60 90 0.8 0.5–1.1 84.8 89.9
Other (black, Asian, other) 33 87.9 0.8 0.5–1.1 81.3 94.1
Site
New York 135 89.6 0.8 0.6–1.0 86.7 92
Utah 147 86.4 0.7 0.5–0.9 84.5 87.6
Abbreviations: BMI Body mass index, PDS Pubertal Development Scale, TS Tanner scale
aPDS is a questionnaire-based assessment of breast development without pictures
bClinical TS is a physical examination of breast development and rated according to the five Tanner stages of breast development
cMissing BMI for 19 girls
Table 3 Mean urinary estrone 1-glucuronide levels and 95% CIs across stages of puberty, according to Pubertal Development Scale
and Sexual Maturation Scale in the LEGACY Girls Study
Stage PDSa SMSb Clinical TSc
No. of subjects Mean (ng/ml) 95% CI No. of subjects Mean (ng/ml) 95% CI No. of subjects Mean (ng/ ml) 95% CI
1 96 1.25 1.11–1.39 116 1.34 1.21–1.47 103 1.29 1.16–1.43
2 36 1.91 1.51–2.32 20 2.07 1.61–2.54 36 1.96 1.56–2.36
3 21 2.34 1.87–2.81 13 2.30 1.76–2.83 11 2.31 1.74–2.89
4 0 4 2.76 1.92–3.59 3 3.94 1.98–3.87
2–4 57 2.07 1.70–2.44 37 2.23 1.83–2.62 50 2.10 1.72–2.47
Abbreviations: PDS Pubertal Development Scale, SMS Sexual Maturation Scale, TS Tanner scale
aPDS is a questionnaire-based assessment of breast development without pictures
bSMS is a questionnaire-based assessment of breast development that uses pictures to illustrate the five Tanner Stages of breast development
cClinical TS is a physical examination of breast development and rated according to the five Tanner stages of breast development
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measures was larger than that in any previous studies
which have assessed mother’s reports of breast develop-
ment [15–18]. Our present results and other recent re-
sults [15] differ from those of a 2002 review of pubertal
assessment methods in which the authors concluded
that the PDS was the least valid method compared with
SMS and other methods. The studies that have shown
the utility of PDS [15, 16] were not included in the re-
view, and none of the studies reviewed included hor-
mone measures [7].
We found that including a urinary estrogen metabolite
in addition to mother’s report further improved the dis-
crimination of breast onset (TS2+). Investigators plan-
ning to assess breast onset may want to consider
incorporating estrogen biomarkers in their pubertal as-
sessment because including E1G in our study improved
the AUC by up to 0.11. However, estrogen alone does
not fully capture clinically assessed breast onset, because
there is substantial overlap in hormone-level distribu-
tions between stages of breast development, as we and
others have shown [15, 34, 35]. Prior studies proposed
that relatively weak correlations between clinician’s and
mother’s reports of breast development and hormone
levels may be due to accounting inadequately for
menstrual cycle phase of biospecimen collection [15,
34]. However, menstrual cycle day is not a source of
variation in our study, because all estrogen measures
were taken from premenarcheal girls. Rather, some of
the wide variation in E1G in TS2 across all assessment
methods may be explained by the inclusion of girls with
transient thelarche as well as girls with permanent the-
larche in this group (see Fig. 1). Girls with transient the-
larche (i.e., the appearance of breast onset that regresses
and appears again) have lower hormone profiles than
girls with permanent thelarche [36]. Whether to include
estrogen measurement in a study design of pubertal de-
velopment depends on the overall intent of the study.
For example, for studies where there is interest in identi-
fying breast onset as a period of breast cancer suscepti-
bility, transient thelarche may be sufficiently captured by
PDS assessment method (and estrogen measurement is
not necessary), because the appearance of breast tissue
marks a period of cell proliferation and rapid breast tis-
sue development.
Because we have shown that estimates of age at breast
onset, typically the first sign of pubertal development,
differ depending on the assessment method, the degree
of misclassification by each method has implications when
Fig. 1 Estrone 1-glucuronide (E1G) concentrations according to concordant and discordant ratings of breast onset in the LEGACY Girls Study.
Mean E1G values were 1.2 ng/ml in girls at T1 and concordant on all three measures (second box plot), 2.3 ng/ml in girls at stage T2+, and con-
cordant on all three measures (last box plot). Mean E1G ranged from 1.5 to 1.8 ng/ml for girls with at least one discordant measure. PDS Pubertal
Development Scale, SMS Sexual Maturation Scale
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using pubertal onset as either an outcome or a parameter
to define the pubertal window of susceptibility. A focus of
pediatric research since the 1990s has been determining
whether there is a secular decline in the age at breast on-
set [9]. Although it appears that there has been a decline
in the age at breast onset [5, 6, 37], one of the main cri-
tiques of early studies of pubertal timing in the United
States was that even the gold standard, clinical breast Tan-
ner staging, was limited if palpation was not performed
[38]. There was concern that physical examination with-
out palpation could not accurately distinguish true TS2
from lipomastia caused by obesity. In our study, two of
the LEGACY sites used clinically trained providers to
measure TS with palpation when necessary to rule out
misclassification due to lipomastia. Measuring clinical TS
may also still be extremely useful in young girls because
the specificity of PDS is still very low in mothers of young
girls. Until the assessment of breast onset is standardized,
one way to draw comparisons across future studies is to
assess breast onset using all three methods in a subset of
the study population, particularly in young girls, so that
final estimates can be adjusted for measurement error
[20]. For studies that cannot implement all three methods,
the measurement error estimates from our study can be
used, as long as the limitations of our study are considered.
Although we did not observe major differences based on
Table 4 Discrimination of the Pubertal Development Scale and Sexual Maturation Scale compared with clinical Tanner stage, as
assessed by AUC in the LEGACY Girls Study
Clinical Tanner stage (T1 vs T2+) AUC (n = 153) Clinical Tanner stage (T1 vs T2) AUC (n = 153)
Model A
PDSa 0.88 0.84
E1G (ng/ml) 0.91 0.87
Race/ethnicity 0.89 0.86
Height (% for age) 0.89 0.84
Weight (% for age) 0.88 0.84
Overweight (> 85th percentile BMI) 0.90 0.86
Family history 0.87 0.83
SMSb 0.78 0.68
E1G (ng/ml) 0.86 0.79
Race/ethnicity 0.81 0.70
Height (% for age) 0.78 0.68
Weight (% for age) 0.78 0.68
Overweight (≥ 85th percentile BMI) 0.80 0.69
Family history 0.78 0.68
Model B
PDSa 0.88 0.84
+ E1G (ng/ml) 0.91 0.87
+ Race/ethnicity 0.91 0.88
+ Overweight (> 85th percentile BMI) 0.92 0.88
+ Family history 0.92 0.88
SMSb 0.78 0.68
+ E1G (ng/ml) 0.86 0.79
+ Race/ethnicity 0.86 0.80
+ Overweight (> 85th percentile BMI) 0.87 0.80
+ Family history 0.87 0.80
Model C
PDS, SMS, E1G 0.91 0.87
Abbreviations: BMI Body mass index, E1G Estrone 1-glucuronide, PDS Pubertal Development Scale, SMS Sexual Maturation Scale
Model A: These models compare mother’s report (PDS or SMS) with clinical TS and add each covariate one at a at time
Model B: These models compare mother’s report (PDS or SMS) with clinical TS and are nested so that each subsequent covariate is added to the previous model
Model C: This model includes PDS, SMS, and E1G to test if the combination of all three measures yields a higher AUC than either PDS + E1G or SMS + E1G
aPDS is a questionnaire-based assessment of breast development without pictures
bSMS is a questionnaire-based assessment of breast development that uses pictures to illustrate the five Tanner Stages of breast development
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breast cancer family history, our enriched study based on
half of the participants having a breast cancer family history
may not be generalizable to other populations. Our study
also does not address whether mother’s report of breast on-
set would be a reliable measure in other countries; however,
mothers living in selected cultures may prefer the PDS be-
cause it does use pictures of breasts.
Ultimately, assessing breast onset accurately in easily scal-
able ways is essential to advancing the understanding of
how early life influences breast cancer risk, as well as un-
derstanding pubertal trends and their health impacts more
broadly. Early breast onset (< 10 years old compared with
11–12 years) is associated with a 23% increased risk of
breast cancer [4]. We found a 2- to 8-month difference in
the age at onset, depending on whether mother’s report of
breast onset was assesed by PDS or SMS. Considering that
a 1-month delay in age at breast onset is related to a 1.6%
decrease in breast cancer risk [4], it is important to consider
the expected effect size of the association in relation to the
size of measurement error. For example, in a recent longi-
tudinal study of breast onset assessed by annual clinical TS,
obesity (BMI > 95th percentile) was associated with an 8.4-
month acceleration in median age of breast onset com-
pared with nonobese U.S. girls (50th to < 85th percentile)
[5]. The median age of breast onset was also 6.7 months
earlier in this population of girls born between 1996 and
2002 compared with girls born between 1980 and 1990 [5,
6]. Both of these studies assessed breast onset using an
annual clinical assessment of breast onset for the majority
of their participants. However, in the study by Biro et al.,
only a subset of girls was assessed semiannually, and the
authors explained that semiannual vs annual assessment
could account for a 3- to 4-month difference in the age of
breast onset between the studies [5]. A clear advantage of
using PDS over clinical TS to assess breast onset are that
(1) it can be implemented more frequently and in a more
cost-effective and scalable manner, and (2) it may yield tigh-
ter estimates of median age of breast onset, especially for
exposures of interest that may have associations of smaller
magnitude than body size or secular time.
Conclusions
Mother’s report of breast onset using PDS is a viable alter-
native to mother’s report using SMS for large-scale epi-
demiological studies of breast onset. The method used for
breast onset assessment alters the estimates of median age
at onset, which has implications for studies of pubertal onset
and studies of breast cancer concerned with pubertal timing.
Including biomarkers related to breast onset, such as urinary
estrogen, can improve the accuracy of pubertal assessments.
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